Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The Robot Concept is experiencing explosive growth! The strongest stock has risen nearly 7 times, and these stocks have all reached new historical highs.

YuTree Technology's Wang Xingxing recently stated that by the end of this year, the entire humanoid robot in the field of AI will reach a new level.

cls.cnFeb 19 01:30 ET

Zhou Zhiping is reassigned, and the weaponry group "gathers" executives from three major state-owned enterprises. Is the countdown to the restructuring of Changan and Dongfeng starting?

① A reporter learned from the official website of China North Industries Group that Zhou Zhiping, the former Director, General Manager, and Deputy Secretary of the Party Committee of the Dongfeng Company, has officially taken office as the Director, General Manager, and Deputy Secretary of the Party Leadership Group of the Equipment Group. ② The Equipment Group has officially "gathered" the former senior executives of three major central enterprise Autos.

cls.cnFeb 17 01:31 ET

Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.

① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.

cls.cnFeb 13 19:04 ET

Hunan Xiang Jia husbandry's output last year was below target, cost reduction efforts are expected to turn profits into losses | Interpretations

① Hunan Xiang Jia husbandry sold approximately 45.28 million live poultry last year, which was basically stable compared to the previous year, with a slight decrease in the slaughter growth rate; ② Thanks to the drop in Fodder costs last year, the company expects to turn losses into profits in 2024.

cls.cnJan 24 09:45 ET

Huadong Medicine has obtained approvals for three new products at the start of the year, which is nearly half of last year's total.|Quick read announcement.

1. Huadong Medicine announced today that three products have received approval for market entry, while a total of seven products were approved last year; 2. Among them, a hyaluronic acid product for medical aesthetics and a chemical drug for the treatment of ovarian cancer received domestic approval, while a medical instrument for assessing kidney function received approval in the USA; 3. Huadong Medicine believes that the approvals will not have a significant impact on the company's current financial situation and operational results.

cls.cnJan 20 10:31 ET